Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Breast Cancer
Interventions: DRUG: Eribulin mesylate
Sponsor: Eisai Korea Inc.